Nelson Advisors: 10 Key Issues Killing European HealthTech, MedTech and Health AI Deals in the Current Market

Nov 17, 2026By Nelson Advisors

NA

European healthcare dealmaking in 2026 is growing in value and shrinking in number. Mergermarket counted 522 European healthcare deals worth €39.9bn in the first half of the year, a 56% rise in value on 50 fewer transactions than the same period of 2025 (Mergermarket). Venture funding has the same shape. 
  
European healthtech raised about €1.6bn of equity in Q3 2026, up roughly 20% year on year, but across 89 rounds rather than 110 (Early Early Stage).
 
The headline numbers hide a split market. A small group of scaled, profitable or category-defining assets attracts fierce competition and premium prices. Everything else, which is most of the lower and mid market, faces longer processes, harder diligence and buyers who are happy to walk away.
  
Time is the clearest symptom. Advisers quoted by Mergermarket describe sale processes that once took a few months now running 12 to 14 months. A process that long rarely dies from one dramatic event. It dies because a certificate lapses, a quarter is missed, a lead investor loses patience or a buyer's investment committee changes its mind.
  
Our article below sets out the ten issues that most often kill European healthtech, medtech and health AI deals today. None is new on its own. What is new is how many of them now turn up in the same transaction. Each section ends with what a seller can do about it, because most of these deal killers are visible, and fixable, long before a buyer finds them.

Source: https://www.healthcare.digital/single-post/nelson-advisors-10-key-issues-killing-european-healthtech-medtech-and-health-ai-deals-in-the-curre

1. The valuation gap that will not close
 
The most common deal killer is still the simplest: seller and buyer disagree on price, and neither moves. Many European healthtech companies raised their last priced round in 2021 or early 2022. That round set a valuation, a preference stack and a set of investor expectations that today's buyers do not recognise.
 
Buyers now price on current revenue quality, margin and cash generation. Sellers price on the last round plus the capital spent since. The two numbers can sit a long way apart before a single diligence question has been asked.

2. MDR and IVDR: reform promised, nothing settled

The second killer is regulatory limbo. The European Commission proposed a major simplification of the Medical Devices Regulation and the In Vitro Diagnostic Regulation on 16 December 2025. Eleven months later it is still a proposal.
  
As of October 2026, the Parliament's lead committee had not voted on its draft report, and the only forward date was an indicative first-reading plenary on 14 December. The Council's June progress report said more work was needed before member states could agree a position (Deemed Consulting). Trilogue cannot start until both sides have one. Until a final text is published, the existing regulations apply in full.

3. The EU AI Act: more time, same double burden
  
Health AI companies got a delay in 2026, not a reprieve. EU co-legislators reached a political agreement on the Digital Omnibus on 7 May 2026. It keeps medical technologies inside the AI Act's high-risk regime. Industrial AI won an exemption; medical devices did not (MedTech Europe).

The application date for high-risk AI embedded in regulated products such as medical devices moves back 12 months to 2 August 2028 (Browne Jacobson). The industry had asked for something different: one compliance pathway, run through the MDR and IVDR. What it got was parallel obligations under both frameworks, with the MDR revision now the main hope for removing the overlap.

4. Reimbursement that stops at the border
  
A product that is paid for in one European country is not paid for in the next. That single fact undermines more healthtech growth plans, and more acquisition models, than any technology risk.
  
Europe has built national fast-track routes, not a European one. Germany's DiGA pathway reimburses lower-risk digital health applications through statutory insurers. France's PECAN scheme offers a one-year, non-renewable coverage window for digital medical devices while evidence is gathered. England relies on NICE assessment and NHS procurement (Nelson Advisors). Each has its own evidence standard, price mechanism and timetable.

5. Slow procurement and revenue that is not what it seems
 
Buyers pay for predictable revenue, and European health systems make revenue hard to predict. One adviser told Mergermarket that pipelines are full but "the problem is visibility for the buyers." That sentence describes most failed healthtech processes of the past year.
  
Selling to hospitals and public health systems is slow. Tenders run for many months, budgets are annual, and a change of government or regional leadership can reset a decision. A company can do everything right commercially and still miss its forecast by two quarters.